ScinoPharm has completed construction of its $113 million plant in Changshu, China. The facilities include an R&D process development center and a multipurpose API manufacturing plant that is compliant with U.S., EU, and Chinese CGMP standards. The new plant will work together with ScinoPharm Taiwan for the production of new international and generic drugs, as well as the domestic demands of the Chinese market. The plant has already received drug production licenses from the Chinese FDA for ...